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I n t r o d u c t i o n.  Local or nodal recurrences after primary combined treatment of advanced head and neck cancer (H&N)
pose as a very difficult clinical problem; almost 50% of these patients do not fulfil the criteria for salvage surgery or any other
radical treatment. Patient groupa are heterogeneous – they differ as to primary treatment and tumour localization, while the
lack of detailed information concerning locoregional advancement, surgical margin status and descriptions of surgical
procedures further complicate the issue. In view of these facts, the best choice for salvage treatment seams to be surgery, followed
by interstitial brachytherapy.
A i m.  To evaluate the tolerance of treatment in patients with local and nodal H&N recurrence treated with salvage surgery and
interstitial HDR brachytherapy.
M a t e r i a l  a n d  m e t h o d.  We evaluated 15 patients with recurrent local or locoregional H&N squamous cell cancer,
primarily treated with surgery and radiotherapy in other institutions treated at the Maria Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology in Gliwice between January 2001 and April 2003. In the entire group the intended secondary
treatment was radical surgery, with implantation of catheters into the tumour bed. The pathological status of surgical margins
in salvage surgery was negative in 8 patients, close in 4 cases and positive in 3 cases. HDR brachytherapy was started 2 days
after surgery: 10 patients received 2 fractions per day to a total dose of 32-36 Gy and 5 patients – one daily fraction of 5 Gy to
a total dose of 20 Gy. The total treatment time ranged from 4 to 6 days, depending on the schedule.
Re s u l t s.  Partial necrosis of the rotational flap and the free flap was observed in 2 patients. The pectoral muscle flap was used
in 6 cases – for the reconstruction of the floor of the mouth, the tongue, the lower lip and the pharynx, In these cases we
observed no problems with healing. Minor complications in wound healing were observed in 3 patients: 2 required repeated
surgery due to impaired wound healing. Altogether, healing complications were observed in 46.6% of patients, 33.3% of whom
required surgery and 13.3% repeated reconstructive surgery. We did not observe acute radiation toxicity, nor any problems with
the removal of catheters.
C o n c l u s i o n s.  HDR brachytherapy as adjuvant therapy after surgery is a safe method in the treatment of recurrent H&N
cancer associated with an acceptable rate of complications.
Ocena wczesnych powik∏aƒ u chorych z nawrotami miejscowymi i w´z∏owymi
w regionie g∏owy i szyi po leczeniu chirurgicznym skojarzonym z brachyterapià HDR
– doniesienie wst´pne
W s t ´ p.  Zaawansowane wznowy miejscowe lub w´z∏owe nowotworów z∏oÊliwych regionu g∏owy i szyi stanowià szczególnie
trudny problem kliniczny, a oko∏o 50% pacjentów z nawrotem nowotworu nie kwalifikuje si´ do leczenia ratujàcego.
Uwzgl´dniajàc te czynniki oraz sekwencj´ wczeÊniej przeprowadzonego leczenia celowym wydaje si´ kojarzenie chirurgii
z brachyterapià w leczeniu ratujàcym tych˝e chorych.
C e l.  Celem pracy jest ocena tolerancji leczenia skojarzonego chirurgii ratujàcej, z brachyterapià HDR, u chorych z nawrotami
miejscowymi i w´z∏owymi w regionie g∏owy i szyi.
M a t e r i a ∏.  Materia∏ stanowi grupa 15 chorych leczonych w Centrum Onkologii Oddzia∏ w Gliwicach w okresie od stycznia
2001 r. do kwietnia 2003 r. z powodu nawrotu miejscowego bàdê w´z∏owego raka p∏askonab∏onkowego regionu g∏owy i szyi,
uprzednio leczonych poza Centrum Onkologii chirurgicznie i napromienianiem (brachyterapia HDR w sekwencji
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Introduction
Local and nodal recurrences of advanced head and neck
cancers after primary combined treatment (H&N)
continue to be a very difficult clinical problem. Approx.
50% of patients are disqualified from further radical
treatment and have very poor prognosis [1, 2], while
attempts at secondary treatment create many difficulties.
Achieving negative surgical margins during salvage
therapy is a real challenge [3].
The group of patients with recurrent H&N cancer is
highly heterogeneous because of different primary
treatment (surgical procedures and radiotherapy
schedules) and different tumour localization. The lack
of detailed information concerning locoregional
advancement, the status of surgical margins and the
details of the surgical procedure causes further problems.
It seems important to match different therapeutic
methods while local recurrence can be the only symptom
of treatment failure. When considering all these factors,
the best choice seems to be surgery, followed by
interstitial brachytherapy. According to a majority of
publications complications in wound healing are reported
in 36-50% of patients [4-6] and they could be the main
limitations of such a combined treatment.
Aim of study
The aim of this study was to evaluate treatment
tolerance in patients with local and nodal H&N
recurrences treated with salvage surgery and interstitial
HDR brachytherapy.
Material and method
We evaluated a group of 15 patients with recurrent local or
locoregional H&N squamous cell cancer, who were treated at
the MSCMCC in Gliwice between January 2001 and April 2003.
All patients were primarily treated with surgery and radiotherapy
outside our institution and admitted to the MSCMCC with
histopathologically confirmed failure at the primary site and/or
the cervical lymph nodes. Detailed information concerning the
surgical margins and previous therapy was missing in 10 patients.
Brachytherapy was included in salvage treatment planning
because of poor locoregional prognosis and the lack of data
concerning histological dates of first surgical treatment.
Microscopically negative margins obtained during salvage
surgery are considered unreliable and insufficient to withdraw
postoperative brachytherapy. Brachytherapy was used as a means
to decrease the risk of another failure.
In case of the entire group secondary treatment was of
radical intent, with tissue reconstruction performed when
necessary and with implantation of catheters in the postresective
tumour bed (Figures 1, 2). All catheters were implanted in
a previously irradiated area and all underwent interstitial HDR
brachytherapy.
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oko∏ooperacyjnej). Wszystkich chorych operowano z intencjà radykalnà i ewentualnà rekonstrukcjà, implantujàc jednoczasowo
dreny w lo˝´ pooperacyjnà oraz obszar oceniony celem przeprowadzenia oko∏ooperacyjnej brachyterapii HDR. W trakcie
chirurgii ratujàcej uzyskany margines resekowanej wznowy oceniono histopatiologicznie jako radykalny u 8 chorych, jako wàski
u 4 i jako nieradykalny u 3. U 10 chorych dawki frakcyjne podawane by∏y 2 razy dziennie do dawki ca∏kowitej 32-36 Gy,
a u pi´ciu chorych zastosowano frakcjonowanie 1 raz dziennie (Df 5 Gy) do dawki ca∏kowitej 20 Gy. Ca∏kowity czas
brachyterapii wynosi∏ od 4 do 6 dni.
W y n i k i.  Ratujàce leczenie chirurgiczne z oko∏ooperacyjnà brachyterapià HDR by∏o dobrze tolerowane przez chorych.
Powik∏ania gojenia ran pooperacyjnych wystàpi∏y u 46,6% chorych, z czego 33,3% wymaga∏y nast´powych interwencji
chirurgicznych, a u dwóch (13,3%) ponownego zabiegu odtwórczego.
W n i o s k i.  Zastosowanie brachyterapii HDR jako uzupe∏nienia leczenia operacyjnego u chorych na zaawansowanego
raka regionu g∏owy i szyi ze wznowà miejscowà jest post´powaniem bezpiecznym, niezwi´kszajàcym ryzyka wczesnych
powik∏aƒ, a odsetek powik∏aƒ jest akceptowalny w grupie chorych z niekorzystnym rokowaniem.
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Figure 1. Tumor bed after resection of the recurrence
Figure 2. Brachytherapy catheters placed in the tumour bed
The characteristics of the analyzed group are presented
in Table I.
Table I. Material characteristics – TNM staging
No. Age Sex Primary tumour localisation TNM
1 66 M lower lip T2N0
2 59 M lower lip T3N1
3 70 M buccal mucosa T2N0
4 50 M larynx T3N0
5 43 K palate T3N0
6 52 K lower lip T2N0
7 56 M parotid ?
8 60 M lower lip & oral commisure T3N1
9 47 M tongue T2N1
10 61 M lower lip T3N1
11 39 K tonsilla T1N1
12 54 K floor of mouth T2N1
13 49 M maxilla T2/3?N0
14 71 M base of tongue T1N0
15 67 K floor of mouth T3N2
The external beam total dose ranged between 40 and
80 Gy. The time to local and/or nodal recurrence varied between
7 and 56 months (mean: 32 months). Only patients with a good
general performance status (0-2pts ZUBROD.) and patholo-
gically confirmed recurrence were qualified to salvage treatment.
Treatment planning was based on computed tomography and/or
nuclear magnetic resonance. Postressective defects reached
some 10-36 cm. Reconstruction generally based on primary
closure, skin grafting, and locoregional flaps (axial, random and
pedicled). Pedicled pectoral muscle flaps (PMF) were used in
6 cases – for the reconstruction of the floor of the mouth, the
tongue, the lower lip and the pharynx. We observed no
complications during the postoperative period. Microvascular
reconstruction was performed in 2 patients only, and in those
cases the radial forearm free flap was used.
The histopathological status of the surgical margins
obtained during salvage surgery was negative in 8 patients, close
(less than 5 mm) in 4 patients and positive in 3 patients.
Brachytherapy planning was performed with the integrated
brachytherapy planning system (IBU), and based on imaging
analyses performed before treatment. HDR brachytherapy was
started 2 days after surgery. The reference points were
individually chosen (from 4 to 8 mm from the catheter surface),
the dose per fraction range was 3-5 Gy. 10 patients were treated
with 2 fractions per day given with a 6-hour interval (dose per
fraction 3 or 4 Gy) to a total dose of 32-36 Gy. In the case of 5
patients was performed with a single daily fraction of 5 Gy up to
a total dose of 20 Gy. Total treatment time varied from 4 to 6
days, depending on the schedule.
Results
Salvage surgery followed by HDR brachytherapy was
generally well tolerated. Partial tissue necrosis requiring
consequential surgery in order to obtain adequate
functional and aesthetic effects occurred in 2 patients.
During the postoperative period the patients developed
differences in the pallor of the irradiated skin and the
skin graft, depending on the type of reconstruction and
the choice of radiotherapy schedule. Minor complications
in wound healing were observed in 3 patients. 2 patients
had to be re-operated due to problems with wound
healing. Complications were observed in 46.6% of
patients; of these 33.3% required surgery – such as simple
fistula closures with local tissues i.e. buccal mucosa, the
sterno-cleido-mastoideus muscle or neighbouring skin.
We did not observe acute radiation toxicity, nor any
difficulties with the removal of the catheters.
Discussion
Salvage surgery combined with postoperative HDR
brachytherapy is generally well tolerated by patients with
advanced locoregional recurrence of H&N cancer. The
combination of these two methods allows to treat “non-
resectable” recurrent tumors or non-mobile metastatic
nodes and provides an opportunity to achieve wide,
microscopically radical surgical margins [7]. Over the last
few years the role of brachytherapy as a sole modality, or
combined with surgery, has been increasing.
Literature data suggests that the toxicity of
brachytherapy as part of the combined treatment of
advanced or recurrent H&N cancer relates, basically, to
LDR brachytherapy and intraoperative treatment.
Unfortunately, literature data concerning HDR brachy-
therapy is not numerous and bases on small patient
groups [8-10].
Smith et al. have assessed the early complications
of combined treatment (surgery and postoperative HDR
brachytherapy) in 9 patients with advanced H&N
cancer [11]. Prolonged wound healing, flap necrosis
and infections have been described as the most common
reactions. They observed toxicity in over half of the
cases, which is comparable to the complication rate,
which we have observed in patients with primary H&N
cancer treated by surgery and postoperative LDR
brachytherapy.
Park et al. describe the total morbidity rate as 36%,
but among patients who had undergone rotational flap
reconstruction this reaches 56% [5]. In our patient group
the ratio of all complications was 46,6%, comparable to
published data. Problems with graft healing were observed
in 2 patients (13.3%) – both required second grafting. In
literature this kind of complication is described in 12 to
20% of patients after combined salvage treatment [12-
15].
The HDR brachytherapy protocol applied as
adjuvant therapy after surgery in our institution resembles
that presented by Smith et al. – i.e. total doses of 20
to 46Gy fractionated twice daily with at least a 6-hour
gap.
Conclusions
HDR brachytherapy as adjuvant treatment after previous
surgery in patients with advanced, recurrent H&N cancer
is a relatively safe modality and it does not increase the
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risk of early toxicity. The complication rate is acceptable
in patients with poor prognosis.
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